

World Journal of *Virology*

Quarterly Volume 14 Number 1 March 25, 2025



EDITORIAL

Shamim L, Musharaf I, Nashwan AJ. Dexamethasone in coronavirus disease 2019 care: Dosage and utilization insights. *World J Virol* 2025; 14(1): 98765 [DOI: [10.5501/wjv.v14.i1.98765](https://doi.org/10.5501/wjv.v14.i1.98765)]

Nagoba BS, Dhotre SV, Gavkare AM, Mumbre SS, Dhotre PS. Convergence of COVID-19 and recurrent stroke: In-hospital mortality risks explored. *World J Virol* 2025; 14(1): 99904 [DOI: [10.5501/wjv.v14.i1.99904](https://doi.org/10.5501/wjv.v14.i1.99904)]

REVIEW

Cenci Dietrich V, Costa JMC, Oliveira MMGL, Aguiar CEO, Silva LGO, Luz MS, Lemos FFB, de Melo FF. Pathogenesis and clinical management of arboviral diseases. *World J Virol* 2025; 14(1): 100489 [DOI: [10.5501/wjv.v14.i1.100489](https://doi.org/10.5501/wjv.v14.i1.100489)]

MINIREVIEWS

Moliya P, Singh A, Singh N, Kumar V, Sohal A. Insights into gastrointestinal manifestation of human immunodeficiency virus: A narrative review. *World J Virol* 2025; 14(1): 99249 [DOI: [10.5501/wjv.v14.i1.99249](https://doi.org/10.5501/wjv.v14.i1.99249)]

Karanam SK, Nagvishnu K, Uppala PK, Edhi S, Varri SR. Crimean-Congo hemorrhagic fever: Pathogenesis, transmission and public health challenges. *World J Virol* 2025; 14(1): 100003 [DOI: [10.5501/wjv.v14.i1.100003](https://doi.org/10.5501/wjv.v14.i1.100003)]

ORIGINAL ARTICLE**Retrospective Study**

Shahid Y, Butt AS, Jamali I, Ismail FW. Rising incidence of acute hepatitis A among adults and clinical characteristics in a tertiary care center of Pakistan. *World J Virol* 2025; 14(1): 97482 [DOI: [10.5501/wjv.v14.i1.97482](https://doi.org/10.5501/wjv.v14.i1.97482)]

Saeed NK, Almusawi SK, Albaloooshi NA, Al-Beltagi M. Unveiling the impact: COVID-19's influence on bacterial resistance in the Kingdom of Bahrain. *World J Virol* 2025; 14(1): 100501 [DOI: [10.5501/wjv.v14.i1.100501](https://doi.org/10.5501/wjv.v14.i1.100501)]

Observational Study

Pinheiro MG, Alves GGO, Conde MER, Costa SL, Sant'Anna RCS, Antunes IMF, Carneiro MC, Ronzei FS, Scaffo JC, Pinheiro FR, Andre LS, Povoá HC, Baltar VT, Giordani F, Hemerly ES, Alexandre GC, de Paula KC, Watanabe M, Nóbrega ACLD, Lobato JCP, Aguiar-Alves F. Serological surveillance for SARS-CoV-2 antibodies among students, faculty and staff within a large university system during the pandemic. *World J Virol* 2025; 14(1): 100338 [DOI: [10.5501/wjv.v14.i1.100338](https://doi.org/10.5501/wjv.v14.i1.100338)]

Basic Study

Thakur SK, Sinha AK, Sharma SK, Jahan A, Negi DK, Gupta R, Singh S. Prevalence of transfusion transmissible infections among various donor groups: A comparative analysis. *World J Virol* 2025; 14(1): 96098 [DOI: [10.5501/wjv.v14.i1.96098](https://doi.org/10.5501/wjv.v14.i1.96098)]

CASE REPORT

Patel S, Jay J, Pathak P, Antony MA, Thiriveedi M. Septic shock due to cytomegalovirus colitis associated with rituximab use: A case report. *World J Virol* 2025; 14(1): 99923 [DOI: [10.5501/wjv.v14.i1.99923](https://doi.org/10.5501/wjv.v14.i1.99923)]

LETTER TO THE EDITOR

Varama A. Revisiting dexamethasone dosage in COVID-19 management. *World J Virol* 2025; 14(1): 98359 [DOI: [10.5501/wjv.v14.i1.98359](https://doi.org/10.5501/wjv.v14.i1.98359)]

Sarker MS. Rhabdomyolysis-related acute kidney injury in COVID-19: A critical concern. *World J Virol* 2025; 14(1): 100160 [DOI: [10.5501/wjv.v14.i1.100160](https://doi.org/10.5501/wjv.v14.i1.100160)]

ABOUT COVER

Editorial Board Member of *World Journal of Virology*, Saurav Basu, MD, Associate Professor, Indian Institute of Public Health - Delhi, Public Health Foundation of India, Gurugram 122102, India. saurav.basu1983@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Virology* (*WJV*, *World J Virol*) is to provide scholars and readers from various fields of virology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJV mainly publishes articles reporting research results obtained in the field of virology and covering a wide range of topics including arbovirus infections, viral bronchiolitis, central nervous system viral diseases, coinfection, DNA virus infections, viral encephalitis, viral eye infections, chronic fatigue syndrome, animal viral hepatitis, human viral hepatitis, viral meningitis, opportunistic infections, viral pneumonia, RNA virus infections, sexually transmitted diseases, viral skin diseases, slow virus diseases, tumor virus infections, viremia, and zoonoses.

INDEXING/ABSTRACTING

The *WJV* is now abstracted and indexed in PubMed, PubMed Central, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Lei Zhang*, Production Department Director: *Xiang Li*, Cover Editor: *Jim-Lei Wang*.

NAME OF JOURNAL

World Journal of Virology

ISSN

ISSN 2220-3249 (online)

LAUNCH DATE

February 12, 2012

FREQUENCY

Quarterly

EDITORS-IN-CHIEF

Mahmoud El-Bendary, En-Qiang Chen, Kai Wang

EXECUTIVE ASSOCIATE EDITORS-IN-CHIEF

Yu-Chen Fan, Shuai Gao

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2220-3249/editorialboard.htm>

PUBLICATION DATE

March 25, 2025

COPYRIGHT

© 2025 Baishideng Publishing Group Inc

PUBLISHING PARTNER

Department of Hepatology, Qilu Hospital of Shandong University

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

POLICY OF CO-AUTHORS

<https://www.wjgnet.com/bpg/GerInfo/310>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/240>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

PUBLISHING PARTNER'S OFFICIAL WEBSITE

<https://www.qiluhospital.com/list-410-1.html>



Rhabdomyolysis-related acute kidney injury in COVID-19: A critical concern

Md Safiullah Sarker

Specialty type: Virology

Provenance and peer review:

Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's classification

Scientific Quality: Grade A

Novelty: Grade A

Creativity or Innovation: Grade A

Scientific Significance: Grade A

P-Reviewer: Jin H

Received: August 8, 2024

Revised: September 24, 2024

Accepted: October 15, 2024

Published online: March 25, 2025

Processing time: 111 Days and 15.6 Hours



Md Safiullah Sarker, Virology Laboratory, Infectious Diseases Division, Dhaka 1212, Bangladesh

Corresponding author: Md Safiullah Sarker, PhD, Research Scientist, Virology Laboratory, Infectious Diseases Division, 68 Shaheed Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh. ssarker@icddr.org

Abstract

Rhabdomyolysis is a severe condition characterized by the breakdown of muscle tissue leading to the release of intracellular components into the bloodstream. This condition, when associated with acute kidney injury (AKI), can result in significant morbidity and mortality, particularly in the context of coronavirus disease 2019 (COVID-19). This editorial discusses a retrospective study on patients with COVID-19 who developed rhabdomyolysis-related AKI. The study highlights that patients with rhabdomyolysis exhibited higher inflammatory markers, such as C-reactive protein, ferritin, and procalcitonin, and experienced worse clinical outcomes compared to those with other causes of AKI. The findings underscore the importance of early recognition and management of rhabdomyolysis in COVID-19 patients to improve prognosis and reduce mortality rates.

Key Words: Rhabdomyolysis; Acute kidney injury; COVID-19; SARS-CoV-2; Creatine kinase; Inflammation; Prognosis; Mortality

©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Rhabdomyolysis is a significant complication in coronavirus disease 2019 (COVID-19) patients, leading to severe acute kidney injury (AKI) with high mortality rates. This editorial highlight a study that found higher inflammatory markers and worse outcomes in patients with rhabdomyolysis-related AKI compared to other causes of AKI. Early detection and appropriate management are crucial to mitigate the adverse effects of this condition in the context of COVID-19.

Citation: Sarker MS. Rhabdomyolysis-related acute kidney injury in COVID-19: A critical concern. *World J Virol* 2025; 14(1): 100160

URL: <https://www.wjgnet.com/2220-3249/full/v14/i1/100160.htm>

DOI: <https://dx.doi.org/10.5501/wjv.v14.i1.100160>

TO THE EDITOR

Rhabdomyolysis, a syndrome resulting from the breakdown of muscle fibers with the release of muscle cell contents into the bloodstream, can cause life-threatening complications such as acute kidney injury (AKI). In the context of coronavirus disease 2019 (COVID-19), rhabdomyolysis has emerged as a critical concern due to its potential to exacerbate the already complex clinical presentations associated with the virus. This editorial explores the findings of a study conducted on COVID-19 patients who developed rhabdomyolysis-related AKI and discusses the implications for clinical practice[1-3].

Rhabdomyolysis and COVID-19

The study[1] in question involved 115 COVID-19 patients who developed AKI, 15 of whom were diagnosed with rhabdomyolysis. These patients were found to have significantly higher levels of inflammatory markers, including C-reactive protein (CRP), procalcitonin, and ferritin, compared to those with AKI from other causes. The elevated inflammatory response likely reflects the severity of rhabdomyolysis in the setting of COVID-19 and its contribution to the overall disease burden[4].

Clinical outcomes

Patients with rhabdomyolysis-related AKI had markedly worse clinical outcomes, with a mortality rate of 73.3%, significantly higher than the 18.1% observed in patients with AKI due to other causes[1]. This stark contrast underscores the need for heightened clinical awareness and proactive management strategies for rhabdomyolysis in COVID-19 patients[5].

Implications for practice

The findings from this study[1] suggest that early identification and aggressive management of rhabdomyolysis in COVID-19 patients could be pivotal in improving outcomes. Monitoring markers such as creatine kinase, CRP, and ferritin should be an integral part of the management protocol for COVID-19 patients at risk of rhabdomyolysis[6].

Rhabdomyolysis complicates the clinical course of COVID-19 and significantly increases the risk of mortality in patients who develop AKI. This editorial emphasizes the need for clinicians to be vigilant in recognizing and managing this condition to mitigate its impact on patient outcomes[7].

FOOTNOTES

Author contributions: Sarker MS designed and conceptualized the study, performed data acquisition, analysis, and interpretation, drafted the first version of the manuscript, commented on consecutive versions, and approved the final version.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country of origin: Bangladesh

ORCID number: Md Safiullah Sarker [0000-0002-5320-1274](https://orcid.org/0000-0002-5320-1274).

S-Editor: Liu H

L-Editor: A

P-Editor: Zheng XM

REFERENCES

- 1 Murt A, Altiparmak MR. Rhabdomyolysis-related acute kidney injury in patients with COVID-19. *World J Virol* 2024; 13: 91107 [PMID: 39323452 DOI: 10.5501/wjv.v13.i3.91107]
- 2 Giannoglou GD, Chatzizisis YS, Misirli G. The syndrome of rhabdomyolysis: Pathophysiology and diagnosis. *Eur J Intern Med* 2007; 18: 90-100 [PMID: 17338959 DOI: 10.1016/j.ejim.2006.09.020]

- 3 **Bagley WH**, Yang H, Shah KH. Rhabdomyolysis. *Intern Emerg Med* 2007; **2**: 210-218 [PMID: 17909702 DOI: 10.1007/s11739-007-0060-8]
- 4 **Haroun MW**, Dieiev V, Kang J, Barbi M, Marashi Nia SF, Gabr M, Eman G, Kajita G, Swedish K. Rhabdomyolysis in COVID-19 Patients: A Retrospective Observational Study. *Cureus* 2021; **13**: e12552 [PMID: 33575135 DOI: 10.7759/cureus.12552]
- 5 **Nadim MK**, Forni LG, Mehta RL, Connor MJ Jr, Liu KD, Ostermann M, Rimmelé T, Zarbock A, Bell S, Bihorac A, Cantaluppi V, Hoste E, Husain-Syed F, Germain MJ, Goldstein SL, Gupta S, Joannidis M, Kashani K, Koyner JL, Legrand M, Lumlertgul N, Mohan S, Pannu N, Peng Z, Perez-Fernandez XL, Pickkers P, Prowle J, Reis T, Srisawat N, Tolwani A, Vijayan A, Villa G, Yang L, Ronco C, Kellum JA. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. *Nat Rev Nephrol* 2020; **16**: 747-764 [PMID: 33060844 DOI: 10.1038/s41581-020-00356-5]
- 6 **Mohamed MMB**, Lukitsch I, Torres-Ortiz AE, Walker JB, Varghese V, Hernandez-Arroyo CF, Alqudsi M, LeDoux JR, Velez JCQ. Acute Kidney Injury Associated with Coronavirus Disease 2019 in Urban New Orleans. *Kidney360* 2020; **1**: 614-622 [PMID: 35372932 DOI: 10.34067/KID.0002652020]
- 7 **Hirsch JS**, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, Hazzan AD, Fishbane S, Jhaveri KD; Northwell COVID-19 Research Consortium; Northwell Nephrology COVID-19 Research Consortium. Acute kidney injury in patients hospitalized with COVID-19. *Kidney Int* 2020; **98**: 209-218 [PMID: 32416116 DOI: 10.1016/j.kint.2020.05.006]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: office@baishideng.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

